Sort   by:  
 Page size 
GenomicsKAP1(TRIM28/TIF1beta) represses differentiation-inducible genes in embryonic stem cells through cooperative binding with PRC1(Ring1b/Rnf2) and derepresses pluripotency-associated genes (ChIP-seq)
Embryonic stem (ES) cells express pluripotency-associated genes and repress differentiation-inducible genes. The activities of these genes are coordinately reversed during differentiation. The changes in the transcriptome upon conditional KAP1 knockout in ES cells overlapped with the changes durin...
ORGANISM(S): Mus musculus 
2014-07-29 | E-GEOD-56628 | biostudies-arrayexpress
UnknownThe Biological Properties and Potential Interacting Proteins of d-Alanyl-d-alanine Ligase A from Mycobacterium tuberculosis.
Not available
S-EPMC6017538 | biostudies-literature
UnknownRutin-Whey Protein Nanoparticles Inhibit D-Galactose-Induced Skeletal Muscle Dysfunction by Modulating Gut Microbiota and Metabolic Pathways.
Not available
S-EPMC12113907 | biostudies-literature
UnknownVitamin D receptor activation protects against myocardial reperfusion injury through inhibition of apoptosis and modulation of autophagy.
Not available
S-EPMC4346660 | biostudies-literature
UnknownPreferential expression of cytochrome CYP CYP2R1 but not CYP1B1 in human cord blood hematopoietic stem and progenitor cells.
Not available
S-EPMC4629107 | biostudies-literature
UnknownImmunotherapies for Anti-N-M-methyl-D-aspartate Receptor Encephalitis: Multicenter Retrospective Pediatric Cohort Study in China.
Not available
S-EPMC8276978 | biostudies-literature
ProteomicsMapping the Interactome of KRAS and Its G12C/D/V Mutants by Integrating TurboID Proximity Labeling with Quantitative Proteomics
RAS is one of the most frequently mutated proto-oncogenes in human malignancies, with mutation sites and subtypes exhibiting tumor-type dependent distribution. Oncogenic RAS mutations will maintain continuously GTP-bound activation states that leading to dysregulation of downstream signaling, ultima...
ORGANISM(S): Homo sapiens (Human) 
2025-06-09 | PXD062101 | Pride
Kras interactome  kras g12 mutants  turboid proximity-labeling  quantitative proteomics；metabolic reprogramming 
UnknownPopulation pharmacokinetics and exposure-response analysis of durvalumab in patients with resectable stage II to IIIB (N2) NSCLC in the phase III AEGEAN study.
Not available
S-EPMC12930014 | biostudies-literature
UnknownDisitamab vedotin combined with toripalimab and radiotherapy for multimodal organ-sparing treatment of muscle invasive bladder cancer: a proof-of-concept study.
Not available
S-EPMC12355133 | biostudies-literature
UnknownMapping the Interactome of KRAS and Its G12C/D/V Mutants by Integrating TurboID Proximity Labeling with Quantitative Proteomics.
Not available
S-EPMC12109396 | biostudies-literature
Sort   by:  
 Page size